Biodyne Co

Biodyne Co Current Liabilities

The Current Liabilities of Biodyne Co (314930.KQ) as of Nov 3, 2026 is 386.62 M KRW. In the previous year, Current Liabilities was 329.63 M KRW — a change of 17.29% (higher).

Current Liabilities

386.62 MKRW

YoY

17.29%

Last updated:

Current Liabilities of Biodyne Co is 2025 386.62 M KRW. Current Liabilities of Biodyne Co was 2024 329.63 M KRW. It decreases by 17.29% higher compared to the previous year.

The Biodyne Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
8.04 B KRW
Jan 1, 2019
2.21 B KRW
Jan 1, 2020
5.58 B KRW
Jan 1, 2021
7.31 B KRW
Jan 1, 2022
1.25 B KRW
Jan 1, 2023
297.79 M KRW
Jan 1, 2024
329.63 M KRW
Jan 1, 2025
386.62 M KRW
The Biodyne Co Current Liabilities history
YEARCurrent LiabilitiesYoY
386.62 MKRW+17.29%
329.63 MKRW+10.69%
297.79 MKRW-76.25%
1.25 BKRW-82.86%
7.31 BKRW+31.09%
5.58 BKRW+152.53%
2.21 BKRW-72.52%
8.04 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

Current Liabilities of Biodyne Co is 386.62 M KRW in 2025.

Current Liabilities of Biodyne Co changed from 329.63 M KRW to 386.62 M KRW, representing a 17.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Biodyne Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biodyne Co

All Key Metrics — Biodyne Co